Vascular Complications of Long COVID—From Endothelial Dysfunction to Systemic Thrombosis: A Systematic Review
Top Cited Papers
Open Access
- 31 December 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 433
Abstract
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated not only with respiratory illness but also with profound vascular and coagulation disturbances. Long COVID (LC) is characterized by persistent symptoms such as fatigue, dyspnea, cognitive impairment, and palpitations. Mechanistically, SARS-CoV-2 induces direct endothelial injury, promotes a pro-inflammatory cytokine milieu, and activates platelets, leading to immunothrombosis and impaired fibrinolysis. Consequently, patients exhibit microthrombosis, elevated plasma D-dimer, fibrinogen dysregulation, and persistent hypercoagulability. Clinically, this translates into an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, as well as arterial thrombotic events such as myocardial infarction and stroke, which may persist months after acute infection. Understanding the interplay between endothelial injury, inflammation, and coagulation is crucial for risk stratification and the development of preventive and therapeutic strategies. We conducted a systematic narrative review of the literature, including human clinical and mechanistic studies identified through PubMed, Scopus and Web of Science up to 30 September 2025. This review synthesizes current evidence on vascular complications in LC, highlighting endothelial dysfunction as a central pathophysiological nexus linking the acute phase of SARS-CoV-2 infection with chronic LC manifestations.Keywords
This publication has 140 references indexed in Scilit:
- Antiphospholipid antibodies in patients with COVID-19: a systematic review and meta-analysisJournal of Thrombosis and Thrombolysis, 2025
- Sustained Vascular Inflammatory Effects of SARS-CoV-2 Spike Protein on Human Endothelial CellsInflammation, 2024
- Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysisJournal of Thrombosis and Thrombolysis, 2023
- SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosisClinical Rheumatology, 2023
- New laboratory evidence for the association between endothelial dysfunction and COVID‐19 disease progressionJournal of Medical Virology, 2022
- A comprehensive review of vascular complications in COVID-19Journal of Thrombosis and Thrombolysis, 2021
- The Role of Antiphospholipid Antibodies in COVID-19Current Rheumatology Reports, 2021
- Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?Journal of Thrombosis and Thrombolysis, 2021
- Coagulation dysfunction is associated with severity of COVID‐19: A meta‐analysisJournal of Medical Virology, 2020
- High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort studyIntensive Care Medicine, 2020